https://www.selleckchem.com/pr....oducts/lenalidomide-
We will use RevMan 5.3 software for statistical analysis of the data. The results of this study will provide evidence of anlotinib-containing regimens for advanced SCLC, and provide clinicians and patients with another convenient and effective treatment regimen for SCLC. This meta-analysis will be submitted to a peer-reviewed journal for publication. This meta-analysis will provide clinical evidence of anlotinib-containing regimens for advanced SCLC, which may or may not be found for anlotinib use. INPLASY202110034. INPLASY20
Curtir
Comentario
Compartilhar
